Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials

ABSTRACT Introduction Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life. Red blood cell transfusions form the basis of anemia management in myelofibrosis but dependence on transfusions is further associated with po...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruben A. Mesa, Moshe Talpaz, Flora Mazerolle, Boris Gorsh, Manal M'Hari, Antoine Regnault, Catherine Ellis, Zhaohui Wang, Molly Purser, Tom Liu, Bryan Strouse, Dwaipayan Patnaik
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:eJHaem
Subjects:
Online Access:https://doi.org/10.1002/jha2.70075
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Introduction Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life. Red blood cell transfusions form the basis of anemia management in myelofibrosis but dependence on transfusions is further associated with poorer survival and quality of life. Methods Time without transfusion reliance (TWiTR), a method integrating transfusion dependence and survival quality, was applied to three Phase 3 trials of momelotinib in myelofibrosis. Results TWiTR demonstrated that patients treated with momelotinib versus comparators spent more time free from transfusions and anemia events. Conclusion Momelotinib may lead to improved survival quality for patients with myelofibrosis. Trial registration ClinicalTrials.gov identifiers: NCT01969838, NCT02101268, and NCT04173494
ISSN:2688-6146